Logo

Genomica Appoints Former Molecular Simulations CEO to Board

Jun 19, 2001

NEW YORK, June 19 - Genomica said Tuesday it had appointed Michael Savage, formerly CEO of Molecular Simulations, to its board of directors.

Savage will replace Arnold Levine, who is joining Genomica's scientific advisory board.

Savage was CEO of Molecular Simulations for eight years before the company was acquired by Pharmacopeia in 1998.

Genomica of Boulder, Colo., develops and markets software products and services, designed to enable pharmaceutical and biotechnology researchers to accelerate the drug discovery and development process.

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.